Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2011

Open Access 01-12-2011 | Original investigation

Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure-a randomized study

Authors: Britt Falskov, Thomas Steffen Hermann, Jakob Raunsø, Buris Christiansen, Christian Rask-Madsen, Atheline Major-Pedersen, Lars Køber, Christian Torp-Pedersen, Helena Dominguez

Published in: Cardiovascular Diabetology | Issue 1/2011

Login to get access

Abstract

Background

Carvedilol has been shown to be superior to metoprolol tartrate to improve clinical outcomes in patients with heart failure (HF), yet the mechanisms responsible for these differences remain unclear. We examined if there were differences in endothelial function, insulin stimulated endothelial function, 24 hour ambulatory blood pressure and heart rate during treatment with carvedilol, metoprolol tartrate and metoprolol succinate in patients with HF.

Methods

Twenty-seven patients with mild HF, all initially treated with carvedilol, were randomized to a two-month treatment with carvedilol, metoprolol tartrate or metoprolol succinate. Venous occlusion plethysmography, 24-hour blood pressure and heart rate measurements were done before and after a two-month treatment period.

Results

Endothelium-dependent vasodilatation was not affected by changing from carvedilol to either metoprolol tartrate or metoprolol succinate. The relative forearm blood flow at the highest dose of serotonin was 2.42 ± 0.33 in the carvedilol group at baseline and 2.14 ± 0.24 after two months continuation of carvedilol (P = 0.34); 2.57 ± 0.33 before metoprolol tartrate treatment and 2.42 ± 0.55 after treatment (p = 0.74) and in the metoprolol succinate group 1.82 ± 0.29 and 2.10 ± 0.37 before and after treatment, respectively (p = 0.27). Diurnal blood pressures as well as heart rate were also unchanged by changing from carvedilol to metoprolol tartrate or metoprolol succinate.

Conclusion

Endothelial function remained unchanged when switching the beta blocker treatment from carvedilol to either metoprolol tartrate or metoprolol succinate in this study, where blood pressure and heart rate also remained unchanged in patients with mild HF.

Trial registration

Current Controlled Trials NCT00497003
Appendix
Available only for authorised users
Literature
1.
go back to reference Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003, 362 (9377): 7-13. 10.1016/S0140-6736(03)13800-7.CrossRefPubMed Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003, 362 (9377): 7-13. 10.1016/S0140-6736(03)13800-7.CrossRefPubMed
2.
go back to reference Erbs S, Gielen S, Linke A, Mobius-Winkler S, Adams V, Baither Y, Schuler G, Hambrecht R: Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy. Am Heart J. 2003, 146 (2): 280-5. 10.1016/S0002-8703(03)00184-4.CrossRefPubMed Erbs S, Gielen S, Linke A, Mobius-Winkler S, Adams V, Baither Y, Schuler G, Hambrecht R: Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy. Am Heart J. 2003, 146 (2): 280-5. 10.1016/S0002-8703(03)00184-4.CrossRefPubMed
3.
go back to reference Meyer B, Mortl D, Strecker K, Hulsmann M, Kulemann V, Neunteufl T, Pacher R, Berger R: Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol. 2005, 46 (6): 1011-8. 10.1016/j.jacc.2005.04.060.CrossRefPubMed Meyer B, Mortl D, Strecker K, Hulsmann M, Kulemann V, Neunteufl T, Pacher R, Berger R: Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. J Am Coll Cardiol. 2005, 46 (6): 1011-8. 10.1016/j.jacc.2005.04.060.CrossRefPubMed
4.
go back to reference Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A: Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005, 111 (3): 310-4. 10.1161/01.CIR.0000153349.77489.CF.CrossRefPubMed Katz SD, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A: Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005, 111 (3): 310-4. 10.1161/01.CIR.0000153349.77489.CF.CrossRefPubMed
5.
go back to reference Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F: Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism. 1991, 40 (9): 972-7. 10.1016/0026-0495(91)90075-8.CrossRefPubMed Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F: Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism. 1991, 40 (9): 972-7. 10.1016/0026-0495(91)90075-8.CrossRefPubMed
6.
go back to reference Swan JW, Anker SD, Walton C, Godsland IF, Clark LA, Leyva F, Stevenson JC, Coats AJ: Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997, 30 (2): 527-32. 10.1016/S0735-1097(97)00185-X.CrossRefPubMed Swan JW, Anker SD, Walton C, Godsland IF, Clark LA, Leyva F, Stevenson JC, Coats AJ: Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997, 30 (2): 527-32. 10.1016/S0735-1097(97)00185-X.CrossRefPubMed
7.
go back to reference Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Jama. 2004, 292 (18): 2227-36. 10.1001/jama.292.18.2227.CrossRefPubMed Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Jama. 2004, 292 (18): 2227-36. 10.1001/jama.292.18.2227.CrossRefPubMed
8.
go back to reference Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A: Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007, 93 (8): 968-73. 10.1136/hrt.2006.092379.PubMedCentralCrossRefPubMed Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A: Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007, 93 (8): 968-73. 10.1136/hrt.2006.092379.PubMedCentralCrossRefPubMed
9.
go back to reference Kveiborg B, Hermann TS, Major-Pedersen A, Christiansen B, Rask-Madsen C, Raunso J, Kober L, Torp-Pedersen C, Dominguez H: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes-a randomized study. Cardiovasc Diabetol. 9: 21. Kveiborg B, Hermann TS, Major-Pedersen A, Christiansen B, Rask-Madsen C, Raunso J, Kober L, Torp-Pedersen C, Dominguez H: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes-a randomized study. Cardiovasc Diabetol. 9: 21.
10.
go back to reference Sanderson JE, Leung LY, Chan SK, Yip GW, Fung JW, Yu CM: Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?. Eur J Heart Fail. 2005, 7 (5): 874-7. 10.1016/j.ejheart.2005.03.002.CrossRefPubMed Sanderson JE, Leung LY, Chan SK, Yip GW, Fung JW, Yu CM: Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?. Eur J Heart Fail. 2005, 7 (5): 874-7. 10.1016/j.ejheart.2005.03.002.CrossRefPubMed
11.
go back to reference Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C, Torp-Pedersen C: Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001, 50 (11): 2611-8. 10.2337/diabetes.50.11.2611.CrossRefPubMed Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C, Torp-Pedersen C: Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001, 50 (11): 2611-8. 10.2337/diabetes.50.11.2611.CrossRefPubMed
12.
go back to reference Joannides R, Bellien J, Thuillez C: Clinical methods for the evaluation of endothelial function-- a focus on resistance arteries. Fundam Clin Pharmacol. 2006, 20 (3): 311-20. 10.1111/j.1472-8206.2006.00406.x.CrossRefPubMed Joannides R, Bellien J, Thuillez C: Clinical methods for the evaluation of endothelial function-- a focus on resistance arteries. Fundam Clin Pharmacol. 2006, 20 (3): 311-20. 10.1111/j.1472-8206.2006.00406.x.CrossRefPubMed
13.
go back to reference Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M: Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J. 2000, 140 (5): 753-9. 10.1067/mhj.2000.110093.CrossRefPubMed Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M: Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J. 2000, 140 (5): 753-9. 10.1067/mhj.2000.110093.CrossRefPubMed
14.
go back to reference Nishioka K, Nakagawa K, Umemura T, Jitsuiki D, Ueda K, Goto C, Chayama K, Yoshizumi M, Higashi Y: Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy. Heart. 2007, 93 (2): 247-8.PubMedCentralCrossRefPubMed Nishioka K, Nakagawa K, Umemura T, Jitsuiki D, Ueda K, Goto C, Chayama K, Yoshizumi M, Higashi Y: Carvedilol improves endothelium-dependent vasodilation in patients with dilated cardiomyopathy. Heart. 2007, 93 (2): 247-8.PubMedCentralCrossRefPubMed
15.
go back to reference Ciccone MM, Iacoviello M, Puzzovivo A, Scicchitano P, Monitillo F, De Crescenzo F, Caragnano V, Sassara M, Quistelli G, Guida P, Favale S: Clinical correlates of endothelial function in chronic heart failure. Clin Res Cardiol. 100 (6): 515-21. Ciccone MM, Iacoviello M, Puzzovivo A, Scicchitano P, Monitillo F, De Crescenzo F, Caragnano V, Sassara M, Quistelli G, Guida P, Favale S: Clinical correlates of endothelial function in chronic heart failure. Clin Res Cardiol. 100 (6): 515-21.
16.
go back to reference Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 305 (24): 2556-64. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 305 (24): 2556-64.
17.
go back to reference Schafer A, Fraccarollo D, Tas P, Schmidt I, Ertl G, Bauersachs J: Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism. Eur J Heart Fail. 2004, 6 (2): 151-9. 10.1016/j.ejheart.2003.10.009.CrossRefPubMed Schafer A, Fraccarollo D, Tas P, Schmidt I, Ertl G, Bauersachs J: Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism. Eur J Heart Fail. 2004, 6 (2): 151-9. 10.1016/j.ejheart.2003.10.009.CrossRefPubMed
18.
go back to reference Kostis JB, Sanders M: The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens. 2005, 18 (5 Pt 1): 731-7.CrossRefPubMed Kostis JB, Sanders M: The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens. 2005, 18 (5 Pt 1): 731-7.CrossRefPubMed
19.
go back to reference Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, Ocampo O: Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol. 2000, 35 (1): 45-50. 10.1016/S0735-1097(99)00504-5.CrossRefPubMed Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, Ocampo O: Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol. 2000, 35 (1): 45-50. 10.1016/S0735-1097(99)00504-5.CrossRefPubMed
Metadata
Title
Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure-a randomized study
Authors
Britt Falskov
Thomas Steffen Hermann
Jakob Raunsø
Buris Christiansen
Christian Rask-Madsen
Atheline Major-Pedersen
Lars Køber
Christian Torp-Pedersen
Helena Dominguez
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2011
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-10-91

Other articles of this Issue 1/2011

Cardiovascular Diabetology 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.